A5001850505- Systemic Lupus Erythematosus Research
- Renal Diseases and Glomerulopathies
- Genetic and Kidney Cyst Diseases
- Atherosclerosis and Cardiovascular Diseases
- Liver Diseases and Immunity
- Systemic Sclerosis and Related Diseases
- Inflammatory Bowel Disease
- Pediatric Urology and Nephrology Studies
- Cytokine Signaling Pathways and Interactions
- Genetic Syndromes and Imprinting
- Hedgehog Signaling Pathway Studies
- Peripheral Neuropathies and Disorders
- Renal cell carcinoma treatment
- Cytomegalovirus and herpesvirus research
- MRI in cancer diagnosis
- Monoclonal and Polyclonal Antibodies Research
- Rheumatoid Arthritis Research and Therapies
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Acute Myocardial Infarction Research
- Advanced Proteomics Techniques and Applications
- Children's Physical and Motor Development
- Renal and Vascular Pathologies
- Dermatological and Skeletal Disorders
- Fetal and Pediatric Neurological Disorders
- Celiac Disease Research and Management
National and Kapodistrian University of Athens
2019-2024
University General Hospital Attikon
2020-2024
University of Cambridge
2023
General Hospital of Athens G. Genimatas
2017-2022
General Hospital of Attica
2022
Our objective was to update the EULAR recommendations for management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity prevention flares. Hydroxychloroquine is recommended all patients with lupus, dose not exceeding 5 mg/kg real body weight. During chronic...
Objective To update the 2012 EULAR/ERA–EDTA recommendations for management of lupus nephritis (LN). Methods Following EULAR standardised operating procedures, a systematic literature review was performed. Members multidisciplinary Task Force voted independently on their level agreeement with formed statements. Results The changes include treatment targets, use glucocorticoids and calcineurin inhibitors (CNIs) end-stage kidney disease (ESKD). target therapy is complete response (proteinuria...
Objectives To update the EULAR recommendations for management of systemic lupus erythematosus (SLE) based on emerging new evidence. Methods An international Task Force formed questions systematic literature reviews (January 2018–December 2022), followed by formulation and finalisation statements after a series meetings. A predefined voting process was applied to each overarching principle recommendation. Levels evidence strengths recommendation were assigned, participants finally provided...
Objective This study aimed to analyse the phenotype of systemic lupus erythematosus (SLE) at first presentation and during follow-up in a newly established SLE cohort based ‘Attikon’ University Hospital. The hospital combines primary, secondary tertiary care for region Western Attica, Greece. Methods comprised mixed prevalent incident 555 Caucasian patients diagnosed with according American College Rheumatology 1997 criteria and/or Systemic Lupus Erythematosus International Collaborating...
Background: Lupus nephritis (LN) affects ~ 40% of patients with systemic lupus erythematosus (SLE) and is associated significant morbidity. New data has emerged since the publication EULAR/ERA-EDTA recommendations for management LN, involving a multidisciplinary panel experts. Objectives: To analyze current evidence, in order to inform 2019 update LN. Methods: According EULAR standardised operating procedures, Medline systematic literature review (SLR) was performed, from January 2012 until...
Objective Changes in the care of patients with SLE dictate a re-evaluation its natural history and risk factors for disease deterioration damage accrual. We sought to decipher predictive phenotype (‘transition’) initially presenting non-severe disease. Methods Patients from ‘Attikon’ cohort duration ≥1 year were included. Disease at diagnosis was categorised as mild, moderate or severe, based on British Isles Lupus Assessment Group manifestations physician judgement. ‘Transition’ severity...
Background Quality of care is receiving increased attention in systemic lupus erythematosus (SLE). We developed quality indicators (QIs) for SLE based on the 2019 update European League Against Rheumatism recommendations. Methods A total 44 candidate QIs corresponding to diagnosis, monitoring and treatment, were independently rated validity feasibility by 12 experts analysed a modified Research Development Corporation/University California Los Angeles model. Adherence final set correlation...
During the past decades, improvements in prevention and management of myocardial infarction, stroke, pulmonary embolism have led to a decline cardiovascular mortality general population. However, it is unknown whether patients receiving dialysis also benefited from these improvements.To assess rates for large cohort European compared with population.In this study, adult who started between 1998 2015 11 countries providing data Renal Association Registry were followed up 3 years. Data...
<h3>Background</h3> Recommendations for the treatment of systemic lupus erythematosus (SLE) were published by EULAR in 2008. Advances strategies and goals called an update these recommendations, capitalizing on strengths experience from previous projects. <h3>Objectives</h3> To recommendations management SLE. <h3>Methods</h3> Systematic literature review (01/2007-12/2017) followed Delphi method to form questions, elicit expert opinions reach consensus. <h3>Results</h3> Treatment SLE aims at...
<h3>Background</h3> SLE phenotype, severity and prognosis varies widely, while its course, pattern of cannot be predicted with confidence. <h3>Objectives</h3> We analyzed the phenotype patterns a cohort in Attica area Greece, based "Attikon" University Hospital, assessed whether these change over course disease. <h3>Methods</h3> Retrospective study 512 Caucasian patients fulfilling ACR 1997 and/or SLICC 2012 criteria. Data on clinical damage index (SDI) were recorded for each patient at time...
Abstract BACKGROUND AND AIMS A small percentage of patients with autosomal dominant polycystic kidney disease (ADPKD) have no clear family history. The clinical course and prognosis the in this subgroup may be different. present study investigates progression prognostication end-stage renal (ESRD) a large cohort without history ADPKD. METHOD This enrolled 291 who were being followed specialized outpatient ADPKD clinic. Patients having total more than 10 cysts recent magnetic resonance...
Background: Up to 40% of systemic lupus erythematosus (SLE) patients develop kidney disease, which represents a major cause morbidity. Objectives: To update the 2012 EULAR/ERA-EDTA recommendations for management nephritis (LN). Methods: We followed EULAR standardised operating procedures publication treatment recommendations. Delphi-based methodology led 15 questions systematic literature review (SLR), was undertaken by three fellows. Results: The changes include targets, use glucocorticoids...